Peptron Inc (087010) - Total Liabilities
Based on the latest financial reports, Peptron Inc (087010) has total liabilities worth ₩37.42 Billion KRW (≈ $25.36 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 087010 cash flow metrics to assess how effectively this company generates cash.
Peptron Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Peptron Inc's total liabilities have evolved over time, based on quarterly financial data. Check Peptron Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Peptron Inc Competitors by Total Liabilities
The table below lists competitors of Peptron Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Corporativo Fragua S.A.B. de C.V
MX:FRAGUAB
|
Mexico | MX$15.09 Billion |
|
Diebold Nixdorf, Incorporated
NYSE:DBD
|
USA | $2.75 Billion |
|
Gaon Cable
KO:000500
|
Korea | ₩791.47 Billion |
|
Shanghai Huafon Aluminium Corp
SHG:601702
|
China | CN¥3.11 Billion |
|
Chicony Electronics Co Ltd
TW:2385
|
Taiwan | NT$51.36 Billion |
|
Hainan Drinda Automotive Trim Co Ltd
SHE:002865
|
China | CN¥12.74 Billion |
|
Fortior Technology (Shenzhen) Co. Ltd. A
SHG:688279
|
China | CN¥149.60 Million |
|
LuxNet
TWO:4979
|
Taiwan | NT$1.64 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Peptron Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Peptron Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Peptron Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Peptron Inc (2014–2024)
The table below shows the annual total liabilities of Peptron Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩17.18 Billion ≈ $11.65 Million |
+4.98% |
| 2023-12-31 | ₩16.37 Billion ≈ $11.09 Million |
+7.94% |
| 2022-12-31 | ₩15.17 Billion ≈ $10.28 Million |
-2.70% |
| 2021-12-31 | ₩15.59 Billion ≈ $10.56 Million |
-61.58% |
| 2020-12-31 | ₩40.57 Billion ≈ $27.49 Million |
+23.31% |
| 2019-12-31 | ₩32.90 Billion ≈ $22.30 Million |
+23.40% |
| 2018-12-31 | ₩26.66 Billion ≈ $18.07 Million |
+549.70% |
| 2017-12-31 | ₩4.10 Billion ≈ $2.78 Million |
-12.56% |
| 2016-12-31 | ₩4.69 Billion ≈ $3.18 Million |
+5.96% |
| 2015-12-31 | ₩4.43 Billion ≈ $3.00 Million |
+0.77% |
| 2014-12-31 | ₩4.39 Billion ≈ $2.98 Million |
-- |
About Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more